We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Avrobio

News List

Uni of Manchester partners with AVROBIO for Hunter syndrome gene therapy pharmatimes
October 10, 2020
The University of Manchester in the UK has partnered with US-based biotech AVROBIO on the clinical development of an investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.
Magenta, AVROBIO to evaluate antibody drug conjugate MGTA-117 pharmaceutical-technology
May 08, 2020
Magenta Therapeutics has signed an agreement with AVROBIO to evaluate the potential utility of its novel targeted antibody-drug conjugate (ADC) MGTA-117 as a potential conditioning regimen for lentiviral gene therapies.
Avrobio and Magenta Therapeutics Collaborate contractpharma
May 07, 2020
Evaluate targeted antibody-drug conjugate as a potential conditioning regimen for lentiviral gene therapies.